Asymmetric Dimethylarginine as a Vascular Risk Factor in Antiepileptic Drug Treated Individuals

Abstract

Get full access to this article

View all access options for this article.

References

El-Farahaty

El-Mitwalli

Azzam

. Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study. J Child Neurol. 2015;30(4):451–457.

Blackwell

. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem. 2010;47:17–28.

Willeit

Freitag

Laukkanen

. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833.

Gokcil

Bek

. Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment? Epilepsy Res. 2009;87:54–58.

Yücel

Akgün

. Increased asymmetric dimethylarginine level after antiepileptic drug treatment may be independent of the changes in plasma homocysteine level. Seizure. 2012;21:232.

Akgün

Yücel

. Asymmetric dimethylarginine may contribute to vascular risk factors in patients receiving antiepileptic drug treatment. Epilepsia. 2012;53:1846.

Öz

Korkmaz

Alay

. Asymmetric dimethylarginine and vascular risk in patients treated with antiepileptic drugs. Epilepsy Res. 2014;108(10):1960–1961.

Ozdemir

Yakut

Dinleyici

. Serum asymmetric dimethylarginine (ADMA), homocysteine, vitamin B(12), folate levels, and lipid profiles in epileptic children treated with valproic acid. Eur J Pediatr. 2011;170(7):873–877.

Emeksiz

Serdaroglu

Biberoglu

. Assessment of atherosclerosis risk due to the homocysteine- asymmetric dimethylarginine-nitric oxide cascade in children taking antiepileptic drugs. Seizure. 2013;22:124–127.